Physician profile
Nitin Trivedi
NPI 1770543977
$402,512.76
in general payments reported to CMS, 2019-2025
34 companies · $7,516 in 2025
The $7,516 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $66K · 2021: $64K · 2022: $74K · 2023: $34K · 2024: $48K · 2025: $7,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Travel and Lodging: $8,772 · Food and Beverage: $4,149 · Education: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,050.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,724.00 |
| Travel and Lodging | $8,772.17 |
| Food and Beverage | $4,149.09 |
| Education | $1,095.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $243,528.76 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $44,509.28 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30,225.23 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $30,200.09 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $21,804.80 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $11,450.72 | 2019-2020 | |
| Dexcom, INC. | $11,180.76 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Corcept Therapeutics | $3,783.09 | 2019-2025 | Korlym |
| Zealand Pharma US, INC. | $1,600.00 | 2021 | |
| Medtronic Minimed, INC. | $1,286.60 | 2019 | |
| Eli Lilly and Company | $1,050.00 | 2024 | |
| Abbott Laboratories | $374.51 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $264.50 | 2025 | Evenity |
| Kyowa Kirin, INC. | $151.45 | 2024-2025 | Crysvita |
| Medtronic, INC. | $129.60 | 2023-2025 | Minimed 780g, Intellis Adaptivestim, Minimed 630g |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $120.13 | 2023 | |
| Cequr Corporation | $113.27 | 2022 | |
| Bigfoot Biomedical INC | $110.59 | 2023 | Unity Diabetes Management System |
| Ascendis Pharma Endocrinology INC | $88.11 | 2023-2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $76.54 | 2023-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $66.12 | 2022-2023 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $63.18 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $63.00 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.73 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.49 | 2024 | Entyvio |
| Radius Health, INC. | $27.76 | 2023 | Tymlos |
| Madrigal Pharmaceuticals | $26.46 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $22.72 | 2019 | |
| Sequel Med Tech, LLC | $21.11 | 2025 | Twiist |
| Mannkind Corporation | $21.09 | 2022 | |
| Ibsa Pharma INC. | $20.18 | 2025 | Tirosint, Licart, Flector |
| Astellas Pharma US INC | $19.85 | 2025 | Veozah |
| Insulet Corporation | $18.21 | 2022 | |
| Abbvie INC. | $15.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.